Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Osaka, Japan, and New York, March 3, 2021 – Takeda Pharmaceutical Company Limited (TSE.